E Fund Management Co. Ltd. Acquires 6,986 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

E Fund Management Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 47.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,580 shares of the company’s stock after acquiring an additional 6,986 shares during the period. E Fund Management Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $466,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Syndax Pharmaceuticals by 13.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 577,022 shares of the company’s stock worth $12,469,000 after purchasing an additional 70,555 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new position in Syndax Pharmaceuticals during the 4th quarter valued at $37,000. Swiss National Bank boosted its holdings in Syndax Pharmaceuticals by 17.7% during the 4th quarter. Swiss National Bank now owns 142,400 shares of the company’s stock worth $3,077,000 after acquiring an additional 21,400 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in shares of Syndax Pharmaceuticals by 20.1% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 159,803 shares of the company’s stock worth $3,453,000 after acquiring an additional 26,769 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SNDX. JPMorgan Chase & Co. upped their price objective on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. HC Wainwright reiterated a “buy” rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Friday, April 26th. Finally, Scotiabank lowered shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and reduced their price target for the company from $36.00 to $23.00 in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.42.

Syndax Pharmaceuticals Stock Down 3.5 %

NASDAQ:SNDX traded down $0.80 during trading hours on Wednesday, hitting $22.38. 1,105,810 shares of the company’s stock traded hands, compared to its average volume of 1,119,221. Syndax Pharmaceuticals, Inc. has a 52 week low of $11.22 and a 52 week high of $25.34. The business’s fifty day simple moving average is $22.47 and its two-hundred day simple moving average is $20.16. The firm has a market cap of $1.90 billion, a P/E ratio of -7.56 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period in the prior year, the firm earned ($0.62) earnings per share. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.74 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).